Corcept Therapeutics Incorporated or Xencor, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Corcept Therapeutics or Xencor?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Corcept Therapeutics Incorporated and Xencor, Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting a strategic investment in growth and expansion. In contrast, Xencor's expenses increased by approximately 615%, indicating a more aggressive scaling strategy.

Despite the higher growth rate in expenses, Xencor's absolute SG&A costs remain significantly lower than Corcept's, suggesting a more efficient cost management relative to its size. As of 2023, Corcept's SG&A expenses are nearly three times higher than Xencor's, highlighting the different operational scales and strategic priorities of these two companies. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these biotech firms.